Farsad Afshinnia1, Ziad S Zaky2, Manasa Metireddy3, Jonathan H Segal3. 1. Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States fafshin@med.umich.edu. 2. Division of Nephrology, Glickman Urology & Nephrology Institute, Cleveland Clinic, Ohio, United States. 3. Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.
Abstract
UNLABELLED: ♦ BACKGROUND: Reverse epidemiology of blood pressure (BP) in end-stage kidney disease (ESKD) is manifested as higher mortality at lower blood pressure. We hypothesize that this phenomenon is partially mediated by deterioration of cardiac structure and function. ♦ METHODS: Seventy-seven prevalent ESKD patients starting renal replacement therapy on peritoneal dialysis (PD) from 2007 to 2012 were evaluated for the primary outcome of all-cause mortality. Longitudinal data were obtained from 1,930 patient-encounters including monthly clinic BP and serial echocardiograms. Generalized linear mixed models using data from the last observation moving backward, and time-to-event analysis using time-varying Cox-survival models to estimate mortality risk at different blood pressure categories were applied. ♦ RESULTS: There were 39 males (50.6%). Mean age was 51 years (standard deviation [SD] = 15). During follow-up, 20 patients (25%) died. As compared to systolic blood pressure (SBP) of 140-159 mmHg, unadjusted risk of mortality was 7.3 (95% confidence interval [CI]: 1.5-35.7, p = 0.008) at level < 120 mmHg. Systolic BP trended down to an average of 117 mmHg prior to death in non-survivors as compared to 141 mmHg in survivors (p < 0.05). In non-survivors, percentage with concentric left ventricular hypertrophy (LVH) decreased by 20% at the expense of a 20% reciprocal increase in eccentric hypertrophy associated with a 30% increase in percentage with low ejection fraction (EF) (< 50%). After adjusting for EF, risk of mortality at SBP < 120 mmHg attenuated to 3.4 (95% CI: 0.7-17.7, p = 0.14). ♦ CONCLUSION: We conclude that higher mortality associated with lower BP may be mediated in part by worsening heart function in ESKD patients receiving PD.
UNLABELLED: ♦ BACKGROUND: Reverse epidemiology of blood pressure (BP) in end-stage kidney disease (ESKD) is manifested as higher mortality at lower blood pressure. We hypothesize that this phenomenon is partially mediated by deterioration of cardiac structure and function. ♦ METHODS: Seventy-seven prevalent ESKD patients starting renal replacement therapy on peritoneal dialysis (PD) from 2007 to 2012 were evaluated for the primary outcome of all-cause mortality. Longitudinal data were obtained from 1,930 patient-encounters including monthly clinic BP and serial echocardiograms. Generalized linear mixed models using data from the last observation moving backward, and time-to-event analysis using time-varying Cox-survival models to estimate mortality risk at different blood pressure categories were applied. ♦ RESULTS: There were 39 males (50.6%). Mean age was 51 years (standard deviation [SD] = 15). During follow-up, 20 patients (25%) died. As compared to systolic blood pressure (SBP) of 140-159 mmHg, unadjusted risk of mortality was 7.3 (95% confidence interval [CI]: 1.5-35.7, p = 0.008) at level < 120 mmHg. Systolic BP trended down to an average of 117 mmHg prior to death in non-survivors as compared to 141 mmHg in survivors (p < 0.05). In non-survivors, percentage with concentric left ventricular hypertrophy (LVH) decreased by 20% at the expense of a 20% reciprocal increase in eccentric hypertrophy associated with a 30% increase in percentage with low ejection fraction (EF) (< 50%). After adjusting for EF, risk of mortality at SBP < 120 mmHg attenuated to 3.4 (95% CI: 0.7-17.7, p = 0.14). ♦ CONCLUSION: We conclude that higher mortality associated with lower BP may be mediated in part by worsening heart function in ESKD patients receiving PD.
Authors: Jochen G Raimann; Len A Usvyat; Stephan Thijssen; Peter Kotanko; John Rogus; Eduardo Lacson; Nathan W Levin Journal: Kidney Int Date: 2012-01-04 Impact factor: 10.612
Authors: N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger Journal: J Am Soc Echocardiogr Date: 1989 Sep-Oct Impact factor: 5.251
Authors: Kelvin L Lynn; David O McGregor; Todd Moesbergen; Adrian L Buttimore; Judith A Inkster; J Elisabeth Wells Journal: Kidney Int Date: 2002-12 Impact factor: 10.612
Authors: Orrin B Myers; Christopher Adams; Mark R Rohrscheib; Karen S Servilla; Dana Miskulin; Edward J Bedrick; Philip G Zager Journal: J Am Soc Nephrol Date: 2010-10-14 Impact factor: 10.121
Authors: Kamyar Kalantar-Zadeh; Ryan D Kilpatrick; Charles J McAllister; Sander Greenland; Joel D Kopple Journal: Hypertension Date: 2005-02-07 Impact factor: 10.190
Authors: Udaya P Udayaraj; Retha Steenkamp; Fergus J Caskey; Chris Rogers; Dorothea Nitsch; David Ansell; Charles R V Tomson Journal: Am J Kidney Dis Date: 2008-11-22 Impact factor: 8.860